Trending Now - FDA Considers Relaxing Restrictions on Controversial Peptides
WHO:
ABC News - Health Secretary Robert F. Kennedy Jr. has discussed using peptides for his own injuries.
AP News - Dr. Peter Lurie, a former FDA official, stated that allowing peptides on the market without clinical testing poses a "profound threat" to the FDA's drug vetting system.
ABC News - The Food and Drug Administration (FDA) is involved in the decision-making process regarding peptide injections.
ABC News - Health Secretary Robert F. Kennedy Jr. is advocating for the easing of restrictions on peptides.
ABC News - Gary Brecka, a self-described “longevity expert,” supports the use of peptides and sells them through his website.
AP News - Dr. Peter Lurie, a former FDA official, expressed concerns about the implications of easing restrictions on peptides.
WHAT:
CBS News - The FDA will soon remove certain peptides from a restrictive list reserved for unapproved, high-risk drugs.
AP News - The FDA's pharmacy panel currently has a number of vacancies that Kennedy could fill before the July meeting.
ABC News - The FDA will hold a meeting in July 2026 to consider easing restrictions on more than seven peptide injections.
ABC News - The FDA is reviewing whether peptides like BPC-157 and TB-500 should be moved from a restrictive category for risky drugs.
AP News - The FDA added nearly 20 popular peptides to a list of substances that should not be produced by compounding pharmacies in 2023.
AP News - The FDA cited significant safety risks associated with these peptides, including cancer and organ problems.
WHERE:
ABC News - The FDA meeting will take place in Washington, D.C.
WHEN:
ABC News - The FDA meeting to discuss peptide restrictions is scheduled for July 2026.
AP News - The FDA added peptides to the restricted substances list in 2023.
WHY:
AP News - Kennedy has echoed concerns about the unintended consequences of FDA regulation, stating, "With the gray market you have no idea if you’re getting a good product."
ABC News - Health Secretary Kennedy aims to loosen regulations on peptides, which are marketed for muscle building, injury healing, and anti-aging.
AP News - The compounding industry argues that FDA restrictions have led to an illicit market for imported chemicals not subject to U.S. standards.
HOW:
CBS News - Scott Brunner of the Alliance for Pharmacy Compounding noted that even if the panel votes to make the peptides available, the FDA will still have to draft and publish rules on the change.
ABC News - The FDA will ask a panel of outside pharmacy advisers to review the safety and efficacy of the peptides.
AP News - The FDA's pharmacy panel previously voted overwhelmingly against the safety of these peptides for compounding.
(UPDATED April 16, 2026 01:23 UTC)
Health Secretary Robert F. Kennedy Jr. has been discussing the use of peptides for his own injuries, while Dr. Peter Lurie, a former FDA official, warned that allowing these substances on the market without clinical testing could pose a significant threat to the FDA's drug vetting system. The FDA is set to remove certain peptides from a restrictive list of unapproved, high-risk drugs, and Kennedy could fill vacancies on the pharmacy panel before its July meeting. However, even if the panel votes to make the peptides available, Scott Brunner from the Alliance for Pharmacy Compounding emphasized that the FDA will still need to draft and publish new rules regarding this change.
--
(UPDATED April 15, 2026 17:25 UTC)
The Food and Drug Administration is set to hold a meeting in Washington, D.C. in July 20th26 to consider easing restrictions on more than seven peptide injections, including BPC-157 and TB-500, which have been categorized as risky drugs due to significant safety concerns. Health Secretary Robert F. Kennedy Jr. is advocating for these changes, arguing that current regulations have fueled an illicit market for unregulated peptides, while former FDA official Dr. Peter Lurie has raised alarms about the potential health risks associated with easing these restrictions. The FDA plans to consult a panel of outside pharmacy advisers to review the safety and efficacy of these peptides, following a previous vote against their safety for compounding.